157 related articles for article (PubMed ID: 16920946)
1. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice.
Otahal P; Schell TD; Hutchinson SC; Knowles BB; Tevethia SS
J Immunol; 2006 Sep; 177(5):3089-99. PubMed ID: 16920946
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors.
Otahal P; Knowles BB; Tevethia SS; Schell TD
J Immunol; 2007 Nov; 179(10):6686-95. PubMed ID: 17982058
[TBL] [Abstract][Full Text] [Related]
3. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.
Staveley-O'Carroll K; Schell TD; Jimenez M; Mylin LM; Tevethia MJ; Schoenberger SP; Tevethia SS
J Immunol; 2003 Jul; 171(2):697-707. PubMed ID: 12847236
[TBL] [Abstract][Full Text] [Related]
4. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
5. Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice.
Ye X; McCarrick J; Jewett L; Knowles BB
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3916-20. PubMed ID: 8171012
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope.
Ryan CM; Schell TD
J Immunol; 2006 Jul; 177(1):255-67. PubMed ID: 16785521
[TBL] [Abstract][Full Text] [Related]
7. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas.
Schell TD; Knowles BB; Tevethia SS
Cancer Res; 2000 Jun; 60(11):3002-12. PubMed ID: 10850449
[TBL] [Abstract][Full Text] [Related]
8. CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.
Tatum AM; Mylin LM; Bender SJ; Fischer MA; Vigliotti BA; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2008 Sep; 181(6):4406-17. PubMed ID: 18768900
[TBL] [Abstract][Full Text] [Related]
9. In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice.
Schell TD
J Virol; 2004 Feb; 78(4):1751-62. PubMed ID: 14747540
[TBL] [Abstract][Full Text] [Related]
10. An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses.
Bruns M; Wanger J; Utermöhlen O; Deppert W
Oncotarget; 2015 Nov; 6(36):38487-503. PubMed ID: 26513294
[TBL] [Abstract][Full Text] [Related]
11. Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes.
Mylin LM; Schell TD; Roberts D; Epler M; Boesteanu A; Collins EJ; Frelinger JA; Joyce S; Tevethia SS
J Virol; 2000 Aug; 74(15):6922-34. PubMed ID: 10888631
[TBL] [Abstract][Full Text] [Related]
12. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.
Lyman MA; Nugent CT; Marquardt KL; Biggs JA; Pamer EG; Sherman LA
J Immunol; 2005 Mar; 174(5):2563-72. PubMed ID: 15728462
[TBL] [Abstract][Full Text] [Related]
13. Induction of homologous rather than heterologous antigen-specific CD4 T cell responses is critical for functional CD8 T cell responses in mice transgenic for a foreign antigen.
Sabarth N; Chamberlain L; Brett S; Tite J; Craigen J
J Immunol; 2010 Oct; 185(8):4590-601. PubMed ID: 20861346
[TBL] [Abstract][Full Text] [Related]
14. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen.
Schell TD; Tevethia SS
J Immunol; 2001 Dec; 167(12):6947-56. PubMed ID: 11739514
[TBL] [Abstract][Full Text] [Related]
15. Short-term corticosterone treatment decreases the early CD8+ T cell response to simian virus 40 tumor antigen but has no impact on the late CD8+ T cell response.
Yorty JL
Brain Behav Immun; 2013 Feb; 28():139-48. PubMed ID: 23164951
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.
Schell TD; Mylin LM; Georgoff I; Teresky AK; Levine AJ; Tevethia SS
J Virol; 1999 Jul; 73(7):5981-93. PubMed ID: 10364350
[TBL] [Abstract][Full Text] [Related]
17. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
18. Low dose streptozotocin-induced diabetes in rat insulin promoter-mCD80-transgenic mice is T cell autoantigen-specific and CD28 dependent.
Pechhold K; Patterson NB; Blum C; Fleischacker CL; Boehm BO; Harlan DM
J Immunol; 2001 Feb; 166(4):2531-9. PubMed ID: 11160314
[TBL] [Abstract][Full Text] [Related]
19. Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.
Srivastava R; Khan AA; Garg S; Syed SA; Furness JN; Vahed H; Pham T; Yu HT; Nesburn AB; BenMohamed L
J Virol; 2017 Jan; 91(2):. PubMed ID: 27847359
[TBL] [Abstract][Full Text] [Related]
20. Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.
Watson AM; Mylin LM; Thompson MM; Schell TD
J Immunol; 2012 Dec; 189(12):5549-60. PubMed ID: 23175697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
